- Home
- INVA vs BHVN Comparison
INVA vs BHVN Comparison
Compare INVA & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVA
- BHVN
- Stock Information
- Founded
- INVA 1996
- BHVN 2013
- Country
- INVA United States
- BHVN United States
- Employees
- INVA N/A
- BHVN N/A
- Industry
- INVA Biotechnology: Pharmaceutical Preparations
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- INVA Health Care
- BHVN Health Care
- Exchange
- INVA Nasdaq
- BHVN Nasdaq
- Market Cap
- INVA 1.1B
- BHVN 1.1B
- IPO Year
- INVA 2004
- BHVN 2017
- Fundamental
- Price
- INVA $21.98
- BHVN $9.18
- Analyst Decision
- INVA Buy
- BHVN Strong Buy
- Analyst Count
- INVA 5
- BHVN 16
- Target Price
- INVA $36.60
- BHVN $32.21
- AVG Volume (30 Days)
- INVA 903.8K
- BHVN 6.4M
- Earning Date
- INVA 11-05-2025
- BHVN 11-10-2025
- Dividend Yield
- INVA N/A
- BHVN N/A
- EPS Growth
- INVA 53.96
- BHVN N/A
- EPS
- INVA 1.52
- BHVN N/A
- Revenue
- INVA $388,521,000.00
- BHVN N/A
- Revenue This Year
- INVA $7.98
- BHVN N/A
- Revenue Next Year
- INVA $11.60
- BHVN $2,079.03
- P/E Ratio
- INVA $13.96
- BHVN N/A
- Revenue Growth
- INVA 10.14
- BHVN N/A
- 52 Week Low
- INVA $16.52
- BHVN $7.48
- 52 Week High
- INVA $22.76
- BHVN $47.75
- Technical
- Relative Strength Index (RSI)
- INVA 69.26
- BHVN 36.30
- Support Level
- INVA $20.68
- BHVN $9.05
- Resistance Level
- INVA $22.48
- BHVN $10.28
- Average True Range (ATR)
- INVA 0.69
- BHVN 0.80
- MACD
- INVA -0.01
- BHVN 0.20
- Stochastic Oscillator
- INVA 70.46
- BHVN 60.00
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.